Cited 0 times in Scipus Cited Count

Efficacy and Safety of Tiropramide in the Treatment of Patients With Irritable Bowel Syndrome: A Multicenter, Randomized, Double-blind, Non-inferiority Trial, Compared With Octylonium.

DC Field Value Language
dc.contributor.authorLee, KN-
dc.contributor.authorLee, OY-
dc.contributor.authorChoi, MG-
dc.contributor.authorSohn, CI-
dc.contributor.authorHuh, KC-
dc.contributor.authorPark, KS-
dc.contributor.authorKwon, JG-
dc.contributor.authorKim, N-
dc.contributor.authorRhee, PL-
dc.contributor.authorMyung, SJ-
dc.contributor.authorLee, JS-
dc.contributor.authorLee, KJ-
dc.contributor.authorPark, H-
dc.contributor.authorLee, YC-
dc.contributor.authorChoi, SC-
dc.contributor.authorJung, HK-
dc.contributor.authorJee, SR-
dc.contributor.authorChoi, CH-
dc.contributor.authorKim, GH-
dc.contributor.authorPark, MI-
dc.contributor.authorSung, IK-
dc.date.accessioned2015-12-09T07:03:44Z-
dc.date.available2015-12-09T07:03:44Z-
dc.date.issued2014-
dc.identifier.issn2093-0879-
dc.identifier.urihttp://repository.ajou.ac.kr/handle/201003/12233-
dc.description.abstractBACKGROUND/AIMS: Antispasmodics such as octylonium are widely used to manage irritable bowel syndrome (IBS) symptoms. However, the efficacy and safety of another antispasmodic, tiropramide, remain uncertain. We aimed to evaluate the efficacy and safety of tiropramide compared with octylonium in patients with IBS.
METHODS: In this multicenter, randomized, non-inferiority trial, 287 patients with IBS (143 receiving tiropramide and 144 octylonium) were randomly allocated to either tiropramide 100 mg or octylonium 20 mg t.i.d (means 3 times a day) for 4 weeks. Primary endpoint was the mean change of abdominal pain from baseline assessed by visual analogue scales (VAS) score after 4 weeks of treatment. Secondary endpoints were the changes in abdominal pain from baseline at week 2 and in abdominal discomfort at weeks 2 and 4, using VAS scores, patient-reported symptom improvement including stool frequency and consistency, using symptom diaries, IBS-quality of life (IBS-QoL), and depression and anxiety, at week 4.
RESULTS: The VAS scores of abdominal pain at week 4, were significantly decreased in both tiropramide and octylonium groups, but the change from baseline did not differ between the 2 groups (difference,-0.26 mm; 95% CI,-4.33-3.82; P = 0.901). Abdominal pain and discomfort assessed using VAS scores, diaries, and IBS-QoL were also improved by both treatments, and the changes from baseline did not differ. The incidence of adverse events was similar in the 2 groups, and no severe adverse events involving either drug were observed.
CONCLUSIONS: Tiropramide is as effective as octylonium in managing abdominal pain in IBS, with a similar safety profile.
-
dc.language.isoen-
dc.titleEfficacy and Safety of Tiropramide in the Treatment of Patients With Irritable Bowel Syndrome: A Multicenter, Randomized, Double-blind, Non-inferiority Trial, Compared With Octylonium.-
dc.typeArticle-
dc.identifier.pmid24466452-
dc.identifier.urlhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3895597/-
dc.subject.keywordAntispasmodic-
dc.subject.keywordIrritable bowel syndrome-
dc.subject.keywordOctylonium-
dc.subject.keywordRome III criteria-
dc.subject.keywordTiropramide-
dc.contributor.affiliatedAuthor이, 광재-
dc.type.localJournal Papers-
dc.identifier.doi10.5056/jnm.2014.20.1.113-
dc.citation.titleJournal of neurogastroenterology and motility-
dc.citation.volume20-
dc.citation.number1-
dc.citation.date2014-
dc.citation.startPage113-
dc.citation.endPage121-
dc.identifier.bibliographicCitationJournal of neurogastroenterology and motility, 20(1). : 113-121, 2014-
dc.identifier.eissn2093-0887-
dc.relation.journalidJ020930879-
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Gastroenterology
Files in This Item:
24466452.pdfDownload

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse